Driving better and safer HER2-specific CARs for cancer therapy

Xianqiang Liu; Nan Zhang; Huan Shi

doi:10.18632/oncotarget.17528

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Driving better and safer HER2-specific CARs for cancer therapy

Xianqiang Liu, Nan Zhang and Huan Shi _

PDF | HTML | How to cite

Oncotarget. 2017; 8:62730-62741. https://doi.org/10.18632/oncotarget.17528

Metrics: PDF 4063 views | HTML 6386 views | ?

Abstract

Xianqiang Liu1,*, Nan Zhang2,* and Huan Shi3

1Department of Breast and Thyroid Surgery, Jinan Central Hospital Affiliated to Shandong University, Jinan, Shandong 250013, P.R. China

2Department of Oncology, Jinan Central Hospital Affiliated to Shandong University, Jinan, Shandong 250013, P.R. China

3Department of Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Sciences, Jinan, Shandong, P.R. China

*These authors contributed equally to this work

Correspondence to:

Huan Shi, email: [email protected]

Keywords: chimeric antigen receptor, HER2, cancer, immunotherapy, toxicity

Received: March 20, 2017 Accepted: April 14, 2017 Published: April 29, 2017

ABSTRACT

Given the clinical efficacy of chimeric antigen receptor (CAR)-based therapy in hematological malignancies, CAR T-cell therapy for a number of solid tumors has been actively investigated. Human epidermal growth factor receptor 2 (HER2) is a well-established therapeutic target in breast, as well as other types of cancer. However, HER2 CAR T cells pose a risk of lethal toxicity including cytokine release syndrome from “on-target, off-tumor” recognition of HER2. In this review, we summarize the development of conventional HER2 CAR technology, the alternative selection of CAR hosts, the novel HER2 CAR designs, clinical studies and toxicity. Furthermore, we also discuss the main strategies for improving the safety of HER2 CAR-based cancer therapies.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 17528

Publication Alerts

Post-Publication Promotion

Publication Discount

Reviews:

Driving better and safer HER2-specific CARs for cancer therapy

Abstract